MapLight Therapeutics, Inc.
MPLT
$13.71
-$0.24-1.72%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 164.95% | 188.05% | 808.62% | 7.94% | -12.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.25% | 173.98% | 266.06% | 50.75% | 53.43% |
| Operating Income | -107.25% | -173.98% | -266.06% | -50.75% | -53.43% |
| Income Before Tax | -101.68% | -171.57% | -274.71% | -54.70% | -62.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -101.68% | -171.57% | -274.71% | -54.70% | -62.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.68% | -171.57% | -274.71% | -54.70% | -62.20% |
| EBIT | -107.25% | -173.98% | -266.06% | -50.75% | -53.43% |
| EBITDA | -107.69% | -175.23% | -268.58% | -51.46% | -54.08% |
| EPS Basic | 96.61% | 95.43% | 91.15% | -48.26% | -60.92% |
| Normalized Basic EPS | 96.61% | 95.42% | 91.16% | -48.26% | -57.33% |
| EPS Diluted | 96.61% | 95.43% | 91.15% | -48.26% | -60.92% |
| Normalized Diluted EPS | 96.61% | 95.42% | 91.16% | -48.26% | -57.33% |
| Average Basic Shares Outstanding | 5,854.31% | 5,844.96% | 4,131.80% | 4.34% | 0.79% |
| Average Diluted Shares Outstanding | 5,854.31% | 5,844.96% | 4,131.80% | 4.34% | 0.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |